ALNY - Alnylam Pharmaceuticals - Stock & Dividends

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company that specializes in discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). This innovative approach enables the company to create treatments that target specific genes and silence their expression, thereby addressing the root cause of various diseases.

The company has a diverse portfolio of marketed products, including ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated amyloidosis, AMVUTTRA for the treatment of hATTR amyloidosis, GIVLAARI for the treatment of acute hepatic porphyria, and OXLUMO for the treatment of primary hyperoxaluria type 1. These products have been designed to address specific genetic disorders, offering new hope to patients and their families.

In addition to its marketed products, Alnylam Pharmaceuticals has a robust pipeline of investigational therapies in various stages of development. These include patisiran for the treatment of transthyretin amyloidosis with cardiomyopathy, cemdisiran for the treatment of complement-mediated diseases, and Belcesiran for the treatment of alpha-1 liver disease, among others. The company is also exploring the potential of RNAi therapeutics in treating complex diseases such as Alzheimer's disease, hypertension, and non-alcoholic steatohepatitis (NASH).

Alnylam Pharmaceuticals has established strategic collaborations with leading pharmaceutical companies, including Regeneron Pharmaceuticals, Inc. and Roche, to accelerate the discovery, development, and commercialization of RNAi therapeutics. The company has also entered into license and collaboration agreements with Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. to expand its reach and capabilities.

Founded in 2002, Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, and has become a pioneer in the field of RNAi therapeutics. With its commitment to innovation and patient-centric approach, the company is poised to make a significant impact in the treatment of genetic diseases and beyond.